

Basic information

2021/2601(DEA)

DEA - Delegated acts procedure

Inclusion of the new psychoactive substances methyl 3,3-dimethyl-2-[[1-(pent-4-en-1-yl)-1H-indazole-3-carbonyl]amino]butanoate (MDMB-4en-PINACA) and methyl 2-[[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (4F-MDMB-BICA) in the definition of 'drug'

Subject

4.20.03 Drug addiction, alcoholism, smoking
7.30.30.04 Action to combat drugs and drug-trafficking

Procedure completed - delegated act enters into force

Key players

European Parliament

Committee responsible

Rapporteur

Appointed

LIBE

Civil Liberties, Justice and Home Affairs

Key events

Date	Event	Reference	Summary
12/03/2021	Non-legislative basic document published	C(2021)01570	
12/03/2021	Initial period for examining delegated act 2 month(s)		
24/03/2021	Committee referral announced in Parliament		
22/05/2021	Delegated act not objected by Parliament		

Technical information

Procedure reference	2021/2601(DEA)
Procedure type	DEA - Delegated acts procedure
Procedure subtype	Examination of delegated act
Stage reached in procedure	Procedure completed - delegated act enters into force
Committee dossier	LIBE/9/05608

Documentation gateway

European Commission

Document type	Reference	Date	Summary
Non-legislative basic document	C(2021)01570	12/03/2021	

